Citations

Clear

4610 citation(s) found for "Lu, Brian".

Prevalence and patterns of laxative use in subjects with self-reported constipation: results from a multinational digestive health survey
Lacy, Brian E. , Delfini, Régis, Fladung, Bernward, Delfini, Regis, Lange, Robert

Mayo Clinic

Therapeutic Advances in Gastroenterology | March 4, 2024 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/17562848241232605 | PMID 38445248 Get It

Background: Constipation is characterized by symptoms of straining, hard stool, difficult evacuation, and infrequent bowel movements. Online surveys provide valuable information about patients’ perspectives, symptoms, management, treatment satisfaction, and risk factors. Methods: This survey explored subject experiences involving 20 gastrointestinal (GI) conditions. In total, 20,099 respondents in seven countries with varied cultural and socioeconomic backgrounds participated. Post hoc analysis of ‘self-reported constipation’ and related symptoms experienced within the past 6 months and the last episode of constipation provided data on prevalence, demographics, frequency and duration of episodes and related symptoms, impact on quality of life (QoL), management with or without laxatives, and resulting treatment satisfaction. Results: In total, 10,425 subjects reported constipation within 6 months and 2637 at the last episode. Prevalence was highest in females and younger adults. Most subjects reported various coexisting GI symptoms. Almost 80% of 6865 episodes reported by 5337 subjects occurred every 2–3 months to every 2–3 weeks. A higher frequency of constipation correlated with a greater impact on QoL. On a 10-point scale, the mean impact was 6.4. More than 90% of respondents had episodes ranging from 1 day to 1 week. More than 90% took action; 16% used laxatives, of whom 80.3% were satisfied. Conclusion: Constipation, a highly prevalent disorder, spans cultures and socioeconomic classes. Its chronic recurrence has a significant impact on QoL, resulting in symptom self-management in >90% of subjects. Significantly higher satisfaction rates in subjects treated with than without laxatives reflect subjects’ reports that self-reported constipation can be treated effectively with laxatives.
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
Lu, Cathy , Rosentreter, Ryan E., Delisle, Maxime , White, Mattie, Parker, Claire E. , Premji, Zahra , Baker, Mark E. , Bhatnagar, Gauraang , Begun, Jakob , Bruining, David H. , Bryant, Robert V. , Christensen, Britt , Feagan, Brian G. , Jairath, Vipul , Knudsen, John M. , Kucharzik, Torsten , Maaser, Christian , Novak, Kerri L. , Taylor, Stuart A. , Wilkens, Rune , Rieder, Florian , Jairath, Vipul , Jairath, Vipul , Begun, Jakob , Bryant, Robert, Christensen, Britt , Jairath, V , Knudsen, John, Maconi, Giovanni , Novak, Kerri , Wilkens, Rune , Rieder, Florian , Lu, Cathy , Jairath, V , Jairath, Vipul , Wilson, Stephanie R. , Fletcher, Joel G. , Rimola, Jordi

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 4, 2024 | Volume: 59 | Issue: 8 | Pages: 928-940

10.1111/apt.17918 | PMID 38436124 Get It

Summary Background Stricturing Crohn's disease (CD) occurs most commonly in the terminal ileum and poses a clinical problem. Cross‐sectional imaging modalities such as intestinal ultrasound (IUS), computed tomography enterography (CTE), and magnetic resonance enterography (MRE) allow for assessment of the entire bowel wall and associated peri‐enteric findings. Radiologic definitions of strictures have been developed for CTE and MRE; their reliability and responsiveness are being evaluated in index development programs. A comprehensive assessment strategy for strictures using IUS is needed. Aims To provide a detailed summary of definitions, diagnosis and monitoring of strictures on IUS as well as technical aspects of image acquisition. Methods We searched four databases up to 6 January 2024. Two‐stage screening was done in duplicate. We assessed risk of bias using QUADAS‐2. Results There were 56 studies eligible for inclusion. Definitions for strictures on IUS are heterogeneous, but the overall accuracy for diagnosis of strictures is high. The capability of IUS for characterising inflammation versus fibrosis in strictures is not accurate enough to be used in clinical practice or trials. We summarise definitions for improvement of strictures on IUS, and discuss parameters for image acquisition and standardisation. Conclusions This systematic review is the first step for a structured program to develop a stricture IUS index for CD.
Metal artifact reduction sequence-MRI abnormalities in asymptomatic patients with dual-mobility hip prostheses
Chung, Brian , Liu, Kevin C. , Chen, Xiao T. , Lovro, Luke R. , Kistler, Natalie M. , Longjohn, Donald B. , Oakes, Daniel A. , Lieberman, Jay R. , Lovro, Luke R , Heckmann, Nathanael D. , White, Eric A. , Christ, Alexander B.

Mayo Clinic

The Bone & Joint Journal | March 1, 2024 | Volume: 106-B | Issue: 3 Supple A | Pages: 89-96

10.1302/0301-620x.106b3.bjj-2023-0643.r1 | PMID 38423076 Get It

AimsModular dual-mobility (DM) articulations are increasingly used during total hip arthroplasty (THA). However, concerns remain regarding the metal liner modularity. This study aims to correlate metal artifact reduction sequence (MARS)-MRI abnormalities with serum metal ion levels in patients with DM articulations.MethodsA total of 45 patients (50 hips) with a modular DM articulation were included with mean follow-up of 3.7 years (SD 1.2). Enrolled patients with an asymptomatic, primary THA and DM articulation with over two years’ follow-up underwent MARS-MRI. Each patient had serum cobalt, chromium, and titanium levels drawn. Patient satisfaction, Oxford Hip Score, and Forgotten Joint Score-12 (FJS-12) were collected. Each MARS-MRI was independently reviewed by fellowship-trained musculoskeletal radiologists blinded to serum ion levels.ResultsOverall, two patients (4.4%) had abnormal periprosthetic fluid collections on MARS-MRI with cobalt levels > 3.0 μg/l. Four patients (8.9%) had MARS-MRI findings consistent with greater trochanteric bursitis, all with cobalt levels < 1.0 μg/l. A seventh patient had a periprosthetic fluid collection with normal ion levels. Of the 38 patients without MARS-MRI abnormalities, 37 (97.4%) had cobalt levels < 1.0 μg/l, while one (2.6%) had a cobalt level of 1.4 μg/l. One patient (2.2%) had a chromium level > 3.0 μg/l and a periprosthetic fluid collection. Of the 41 patients with titanium levels, five (12.2%) had titanium levels > 5.0 μg/l without associated MARS-MRI abnormalities.ConclusionPeriprosthetic fluid collections associated with elevated serum cobalt levels in patients with asymptomatic DM articulations occur infrequently (4.4%), but further assessment is necessary due to implant heterogeneity.Cite this article: Bone Joint J 2024;106-B(3 Supple A):89–96.
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
Morgan, Todd M. , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chapin, Brian F. , Chen, David Y.T. , Jacene, Heather A. , Kim, Sennett K., Kirkby, Erin, Nathanson, B.J., Posadas, Edwin M. , Morgan, Todd M , Cheng, Heather H. , Chou, Roger , Kamran, Sophia C. , Luckenbaugh, Amy N. , Nathanson, Ben J., Nyame, Yaw A. , Tran, Phuoc T , Chen, Ronald C.

Mayo Clinic

Journal of Urology | February 29, 2024 | Volume: 211 | Issue: 4 | Pages: 518-525

10.1097/ju.0000000000003891 | PMID 38421243 Get It

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy
Morgan, Todd M. , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chapin, Brian F. , Chen, David Y.T. , Jacene, Heather A. , Kim, Sennett K., Kirkby, Erin, Nathanson, B.J., Posadas, Edwin M. , Morgan, Todd M , Cheng, Heather H. , Chou, Roger , Kamran, Sophia C. , Luckenbaugh, Amy N. , Nathanson, Ben J., Nyame, Yaw A. , Tran, Phuoc T , Chen, Ronald C.

Mayo Clinic

Journal of Urology | February 29, 2024 | Volume: 211 | Issue: 4 | Pages: 509-517

10.1097/ju.0000000000003892 | PMID 38421253 Get It

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions
Morgan, Todd M. , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chapin, Brian F. , Chen, David Y.T. , Jacene, Heather A. , Kim, Sennett K., Kirkby, Erin, Nathanson, B.J., Posadas, Edwin M. , Morgan, Todd M , Cheng, Heather H. , Chou, Roger , Kamran, Sophia C. , Luckenbaugh, Amy N. , Nathanson, Ben J., Nyame, Yaw A. , Tran, Phuoc T , Chen, Ronald C.

Mayo Clinic

Journal of Urology | February 29, 2024 | Volume: 211 | Issue: 4 | Pages: 526-532

10.1097/ju.0000000000003890 | PMID 38421252 Get It

Identification of immune cell markers associated with ulcerative colitis histological disease activity in colonic biopsies
Lefèvre, Pavine, Wang, Zhongya , Teft, Wendy A., Viegen, Tanja van, Linggi, Bryan, Jairath, Vipul , Feagan, Brian G. , Pai, Rish K. , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Casteele, Niels Vande

Mayo Clinic

Journal of Clinical Pathology | February 28, 2024 | Volume: 78 | Issue: 9 | Pages: 605-613

10.1136/jcp-2023-209327 | PMID 38418201 Get It

Aims Accurate determination of histological activity in ulcerative colitis (UC) is essential given its diagnostic and prognostic importance. Data on the relationship between histology and immune cell markers are limited. We aimed to evaluate the association between histological disease activity and immune cell marker concentration in colonic biopsies from patients with UC. Methods Sigmoid colon biopsies from 20 patients with UC were retrospectively assessed using the Robarts Histopathology Index (RHI). Targeted mass spectrometry determined the concentration of 18 immune cell markers (cluster of differentiation (CD) 4, CD8, CD19, CD20, CD40, CD56, CD68, CD103, forkhead box p3 (FOXP3), human leucocyte antigen, DR alpha chain (HLA-DRA), interleukin 10 (IL-10), IL-23 subunit alpha (IL-23A), IL-23 receptor (IL-23R), IL-2 receptor alpha chain (IL-2RA), Ki67, lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD-1) and PD ligand 1 (PD-L1)). The association between RHI score and immune cell marker concentration was quantified using Spearman’s rank correlation coefficient (ρ) and related 95% CIs. Results Fourteen of the 18 immune cell marker proteins were detected, with tissue concentration ranging from 0.003 to 11.53 fmol/µg. The overall RHI score was positively correlated with CD19, CD20, CD40, FOXP3, LAG-3, PD-1 and PD-L1 concentration (ρ=0.596–0.799) and negatively correlated with CD56 concentration (ρ=−0.460). There was no significant association between RHI score and CD4, CD8, CD68, CD103, HLA-DRA or Ki67 concentration. Conclusions This study provides insight into the correlation between immune cell marker expression and histological disease activity and the possible molecular and immunological determinants underlying microscopic disease activity in UC.
Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
Jacobs, Jeremy W. , Stephens, Laura D. , Chooljian, David M. , Sharma, Deva , Adkins, Brian D. , Booth, Garrett S. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura

Mayo Clinic

American Journal of Hematology | February 27, 2024 | Volume: 99 | Issue: 6 | Pages: 1016-1018

10.1002/ajh.27275 | PMID 38409818 Get It

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
Wang, Guoqiao , Li, Yan , Xiong, Chengjie , Gordon, Brian A. , Hassenstab, Jason , Aschenbrenner, Andrew J. , Clifford, David B. , Libre‐Guerra, Jorge J., Shi, Xinyu , Mummery, Catherine J. , Dyck, Christopher H. van , Day, Gregg, Ringman, John M. , Fox, Nick C. , Bittner, Tobias , Team, for the DIAN‐TU Study, Day, Gregory S. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Aschenbrenner, Andrew J , Xiong, Chengjie , Benzinger, Tammie L.S. , McDade, Eric , Lah, James J. , Honig, Lawrence S. , Day, Gregg, Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Delmar, Paul , Bateman, Randall J. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | February 24, 2024 | Volume: 20 | Issue: 4 | Pages: 2698-2706

10.1002/alz.13735 | PMID 38400532 Get It

AbstractINTRODUCTIONIncreasing evidence suggests that amyloid reduction could serve as a plausible surrogate endpoint for clinical and cognitive efficacy. The double‐blind phase 3 DIAN‐TU‐001 trial tested clinical and cognitive declines with increasing doses of solanezumab or gantenerumab.METHODSWe used latent class (LC) analysis on data from the Dominantly Inherited Alzheimer Network Trials Unit 001 trial to test amyloid positron emission tomography (PET) reduction as a potential surrogate biomarker.RESULTSLC analysis categorized participants into three classes: amyloid no change, amyloid reduction, and amyloid growth, based on longitudinal amyloid Pittsburgh compound B PET standardized uptake value ratio data. The amyloid‐no‐change class was at an earlier disease stage for amyloid amounts and dementia. Despite similar baseline characteristics, the amyloid‐reduction class exhibited reductions in the annual decline rates compared to the amyloid‐growth class across multiple biomarker, clinical, and cognitive outcomes.DISCUSSIONLC analysis indicates that amyloid reduction is associated with improved clinical outcomes and supports its use as a surrogate biomarker in clinical trials.Highlights We used latent class (LC) analysis to test amyloid reduction as a surrogate biomarker. Despite similar baseline characteristics, the amyloid‐reduction class exhibited remarkably better outcomes compared to the amyloid‐growth class across multiple measures. LC analysis proves valuable in testing amyloid reduction as a surrogate biomarker in clinical trials lacking significant treatment effects.
Patient‐ and proxy‐reported quality of life in advanced dementia with Lewy bodies
Armstrong, Melissa J. , LaBarre, Brian , Sovich, Kaitlin , Maixner, Susan M. , Paulson, Henry L. , Manning, Carol A. , Fields, Julie A. , Lunde, Angela , Forsberg, Leah K. , Taylor, Angela , Paulson, Henry L , LaBarre, Brian , Armstrong, Melissa J , Boeve, Bradley F. , Galvin, James E. , Li, Zhigang

Mayo Clinic

Alzheimer's & Dementia | February 24, 2024 | Volume: 20 | Issue: 4 | Pages: 2719-2730

10.1002/alz.13745 | PMID 38400528 Get It

AbstractINTRODUCTIONLittle is known regarding quality of life (QoL) in dementia with Lewy bodies (DLB), particularly in advanced stages.METHODSDyads of individuals with moderate–advanced DLB and their primary caregivers were recruited from specialty clinics, advocacy organizations, and research registries. The study collected demographics, disease‐related measures, and measures of patient/caregiver experiences.RESULTSThe Quality of Life in Alzheimer's Disease (QoL‐AD) was completed by the person with DLB and the caregiver (proxy) in 61 dyads; 85 dyads had only a proxy‐completed QoL‐AD. Patient‐ and proxy‐reported scores were moderately correlated (r = 0.57, P < 0.0001). Worse patient‐reported QoL correlated with daytime sleepiness, autonomic symptom burden, and behavioral symptoms. Proxy ratings correlated with dementia severity, daytime sleepiness, behavioral symptoms, dependence in activities of daily living, and caregiver experience measures.DISCUSSIONPatient‐ and proxy‐reported quality of life (QoL) should be assessed separately in advanced DLB. Some symptoms associated with QoL have available therapeutic options. Research is needed regarding strategies to optimally improve QoL in DLB.Highlights Patient and proxy quality of life (QoL) ratings had moderate correlation in advanced dementia with Lewy bodies. Daytime sleepiness affected patient‐ and proxy‐reported QoL. Behavioral symptoms affected patient‐ and proxy‐reported QoL. Autonomic symptom burden affected patient‐reported QoL. Dementia severity, dependence, and caregiver experiences affected proxy ratings.